Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711986 | 0.89 | MAOA (0.43) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12261351 | 0.84 | PARP1 (0.51) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10071932 | 0.83 | TNKS2 (0.47) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12261358 | 0.82 | PARP1 (0.46) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL712224 | 0.80 | MAPT (0.41) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL711643 | 0.78 | MAPT (0.43) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL714063 | 0.78 | MAPT (0.50) | MAPTSMN1; SMN2ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL719982 | 0.78 | KMT2A (0.42) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL711989 | 0.78 | MAPT (0.40) | MAOAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10044133 | 0.78 | MAPT (0.43) | MAOAMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | claimed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | TERT, ACIN1, AK2 | MAOA 925/4885MAPT 3490/4885MEN1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.